Amendment No. 5 to Collaboration and License AgreementCollaboration and License Agreement • August 15th, 2016 • Proteostasis Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 5 to Collaboration and License Agreement (this “Amendment No. 5”) is made and effective as of July 31, 2016, by and between Proteostasis Therapeutics, Inc., a corporation existing under the laws of the State of Delaware, having a place of business at 200 Technology Square, 4th Floor, Cambridge, MA 02139 (“PTI”) and Astellas Pharma Inc., a Japanese corporation having its principal place of business at 5-1 Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8411, Japan (“Astellas”). Each of Astellas and PTI is sometimes referred to individually herein as a “Party” and collectively as the “Parties”.
